0K3W Stock Overview
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Myriad Genetics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$18.80 |
| 52 Week High | US$24.13 |
| 52 Week Low | US$14.53 |
| Beta | 1.98 |
| 1 Month Change | -10.87% |
| 3 Month Change | -8.29% |
| 1 Year Change | -13.36% |
| 3 Year Change | -36.01% |
| 5 Year Change | -43.22% |
| Change since IPO | -54.16% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0K3W | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -8.2% | -2.3% | -0.7% |
| 1Y | -13.4% | -29.4% | -1.8% |
Return vs Industry: 0K3W exceeded the UK Biotechs industry which returned -29.6% over the past year.
Return vs Market: 0K3W underperformed the UK Market which returned -2.4% over the past year.
Price Volatility
| 0K3W volatility | |
|---|---|
| 0K3W Average Weekly Movement | 7.6% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0K3W's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 0K3W's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 2,700 | Paul Diaz | www.myriad.com |
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.
Myriad Genetics, Inc. Fundamentals Summary
| 0K3W fundamental statistics | |
|---|---|
| Market cap | US$1.69b |
| Earnings (TTM) | -US$263.30m |
| Revenue (TTM) | US$753.20m |
2.2x
P/S Ratio-6.4x
P/E RatioIs 0K3W overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0K3W income statement (TTM) | |
|---|---|
| Revenue | US$753.20m |
| Cost of Revenue | US$236.20m |
| Gross Profit | US$517.00m |
| Other Expenses | US$780.30m |
| Earnings | -US$263.30m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.91 |
| Gross Margin | 68.64% |
| Net Profit Margin | -34.96% |
| Debt/Equity Ratio | 4.9% |
How did 0K3W perform over the long term?
See historical performance and comparison